<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36928391</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>CDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress.</ArticleTitle><Pagination><StartPage>3783</StartPage><EndPage>3799</EndPage><MedlinePgn>3783-3799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad087</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that affects motor neurons in the spinal cord, brainstem and motor cortex, leading to paralysis and eventually to death within 3-5 years of symptom onset. To date, no cure or effective therapy is available. The role of chronic endoplasmic reticulum stress in the pathophysiology of amyotrophic lateral sclerosis, as well as a potential drug target, has received increasing attention. Here, we investigated the mode of action and therapeutic effect of the endoplasmic reticulum-resident protein cerebral dopamine neurotrophic factor in three preclinical models of amyotrophic lateral sclerosis, exhibiting different disease development and aetiology: (i) the conditional choline acetyltransferase-tTA/TRE-hTDP43-M337V rat model previously described; (ii) the widely used SOD1-G93A mouse model; and (iii) a novel slow-progressive TDP43-M337V mouse model. To specifically analyse the endoplasmic reticulum stress response in motor neurons, we used three main methods: (i) primary cultures of motor neurons derived from embryonic Day 13 embryos; (ii) immunohistochemical analyses of spinal cord sections with choline acetyltransferase as spinal motor neuron marker; and (iii) quantitative polymerase chain reaction analyses of lumbar motor neurons isolated via laser microdissection. We show that intracerebroventricular administration of cerebral dopamine neurotrophic factor significantly halts the progression of the disease and improves motor behaviour in TDP43-M337V and SOD1-G93A rodent models of amyotrophic lateral sclerosis. Cerebral dopamine neurotrophic factor rescues motor neurons in vitro and in vivo from endoplasmic reticulum stress-associated cell death and its beneficial effect is independent of genetic disease aetiology. Notably, cerebral dopamine neurotrophic factor regulates the unfolded protein response initiated by transducers IRE1&#x3b1;, PERK and ATF6, thereby enhancing motor neuron survival. Thus, cerebral dopamine neurotrophic factor holds great promise for the design of new rational treatments for amyotrophic lateral sclerosis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Lorenzo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;ningschr&#xf6;r</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3883-6554</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital W&#xfc;rzburg, 97078 W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Jinhan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4153-3711</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>Liam</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Inselspital University Hospital, University of Bern, CH-3010 Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galli</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>P&#xe4;ivi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;dt von Collenberg</LastName><ForeName>Cora</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital W&#xfc;rzburg, 97078 W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungwa</LastName><ForeName>Simon Tii</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital W&#xfc;rzburg, 97078 W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jablonka</LastName><ForeName>Sibylle</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4517-3760</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital W&#xfc;rzburg, 97078 W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauder</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thau-Habermann</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medicum, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Minerva Foundation Institute for Medical Research, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saxena</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Inselspital University Hospital, University of Bern, CH-3010 Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sendtner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4737-2974</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital W&#xfc;rzburg, 97078 W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saarma</LastName><ForeName>Mart</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5543-7160</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voutilainen</LastName><ForeName>Merja H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-9832-7655</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, FIN-00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D004722">Endoribonucleases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577430">CDNF protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004722" MajorTopicYN="N">Endoribonucleases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059865" MajorTopicYN="N">Endoplasmic Reticulum Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CDNF</Keyword><Keyword MajorTopicYN="N">ER stress</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">motor neurons</Keyword><Keyword MajorTopicYN="N">unfolded protein response</Keyword></KeywordList><CoiStatement>P&#xe4;ivi Lindholm, Mart Saarma and Merja H. Voutilainen are inventors of the CDNF-patent, which is owned by Herantis Pharma Plc. M Saarma is a shareholder of Herantis Pharma Plc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36928391</ArticleId><ArticleId IdType="pmc">PMC10473573</ArticleId><ArticleId IdType="doi">10.1093/brain/awad087</ArticleId><ArticleId IdType="pii">7078992</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C, Saxena S. ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol. 2017;13:477&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">28731040</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin JD, Farg MA, Walker AK, McLean C, Tomas D, Horne MK. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol Dis. 2008;30:400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">18440237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C, Thielen P, Matus S, et al. . XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 2009;23:2294&#x2013;2306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758741</ArticleId><ArticleId IdType="pubmed">19762508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Yamada M, Tanaka H, et al. . Involvement of CHOP, an ER-stress apoptotic mediator, in both human sporadic ALS and ALS model mice. Neurobiol Dis. 2009;36:470&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">19733664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Endoplasmic reticulum stress in motor neurons of the spinal cord in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2010;69:346&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">20448480</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, Scaber J, Ababneh N, et al. . C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia. Stem Cells. 2016;34:2063&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979662</ArticleId><ArticleId IdType="pubmed">27097283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E, Sandoe J, Williams LA, et al. . Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14:781&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Jansen-West K, Xu Y-F, et al. . Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Cabuy E, Caroni P. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci. 2009;12:627&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi H, Almer G, Yamashita S, et al. . Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc Natl Acad Sci U S A. 2006;103:6025&#x2013;6030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458691</ArticleId><ArticleId IdType="pubmed">16595634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitoh H, Kadowaki H, Nagai A, et al. . ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting derlin-1. Genes Dev. 2008;22:1451&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2418582</ArticleId><ArticleId IdType="pubmed">18519638</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinas DB, Rozas P, Martinez Traub F, et al. . Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2018;115:8209&#x2013;8214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6094144</ArticleId><ArticleId IdType="pubmed">30038021</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Soo KY, Sundaramoorthy V, et al. . ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS ONE. 2013;8:e81170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843686</ArticleId><ArticleId IdType="pubmed">24312274</ArticleId></ArticleIdList></Reference><Reference><Citation>de L'Etang A F, Maharjan N, Cordeiro Brana M, et al. . Marinesco-Sjogren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS. Nat Neurosci. 2015;18:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">25559081</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Soo KY, Walker AK, et al. . Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase. Neurobiol Aging. 2012;33:2855&#x2013;2868.</Citation><ArticleIdList><ArticleId IdType="pubmed">22459602</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP, Atkin JD. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:717&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">23172909</ArticleId></ArticleIdList></Reference><Reference><Citation>Couly S, Khalil B, Viguier V, Roussel J, Maurice T, Li&#xe9;vens J-C. Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis. Hum Mol Genet. 2020;29:529&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">31696229</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Perez P, Woehlbier U, Chian RJ, et al. . Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients. Gene. 2015;566:158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5553116</ArticleId><ArticleId IdType="pubmed">25913742</ArticleId></ArticleIdList></Reference><Reference><Citation>Das I, Krzyzosiak A, Schneider K, et al. . Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348:239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490275</ArticleId><ArticleId IdType="pubmed">25859045</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H-Q, Ren M, Jiang H-Z, et al. . Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience. 2014;277:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24699224</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus S, Lopez E, Valenzuela V, Nassif M, Hetz C. Functional contribution of the transcription factor ATF4 to the pathogenesis of amyotrophic lateral sclerosis. PLoS ONE. 2013;8:e66672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715499</ArticleId><ArticleId IdType="pubmed">23874395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm P, Voutilainen MH, Lauren J, et al. . Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature. 2007;448:73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">17611540</ArticleId></ArticleIdList></Reference><Reference><Citation>Norisada J, Hirata Y, Amaya F, Kiuchi K, Oh-Hashi K. A comparative analysis of the molecular features of MANF and CDNF. PLoS ONE. 2016;11:e0146923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731063</ArticleId><ArticleId IdType="pubmed">26820513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl M, Danilova T, Palm E, et al. . MANF Is indispensable for the proliferation and survival of pancreatic beta cells. Cell Rep. 2014;7:366&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254957</ArticleId><ArticleId IdType="pubmed">24726366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakarinen E, Danilova T, V&#xf5;ikar V, et al. . MANF ablation causes prolonged activation of the UPR without neurodegeneration in the mouse midbrain dopamine system. eNeuro. 2020;7:ENEURO.0477-19.2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053174</ArticleId><ArticleId IdType="pubmed">32005751</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakarinen E, Lindholm P, Saarma M, Lindahl M. CDNF and MANF regulate ER stress in a tissue-specific manner. Cell Mol Life Sci. 2022;79:124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8821067</ArticleId><ArticleId IdType="pubmed">35129674</ArticleId></ArticleIdList></Reference><Reference><Citation>Eesmaa A, Yu LY, G&#xf6;&#xf6;s H, et al. . CDNF interacts with ER chaperones and requires UPR sensors to promote neuronal survival. Int J Mol Sci. 2022;23:9489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9408947</ArticleId><ArticleId IdType="pubmed">36012764</ArticleId></ArticleIdList></Reference><Reference><Citation>Airavaara M, Harvey BK, Voutilainen MH, et al. . CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant. 2012;21:1213&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753365</ArticleId><ArticleId IdType="pubmed">21943517</ArticleId></ArticleIdList></Reference><Reference><Citation>Garea-Rodriguez E, Eesmaa A, Lindholm P, et al. . Comparative analysis of the effects of neurotrophic factors CDNF and GDNF in a nonhuman primate model of Parkinson's disease. PLoS ONE. 2016;11:e0149776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763937</ArticleId><ArticleId IdType="pubmed">26901822</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutilainen MH, Back S, Peranen J, et al. . Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol. 2011;228:99&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21185834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm P, Saarma M. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol Psychiatry. 2022;27:1310&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095478</ArticleId><ArticleId IdType="pubmed">34907395</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Tong J, Bi F, Zhou H, Xia X-G. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest. 2012;122:107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248298</ArticleId><ArticleId IdType="pubmed">22156203</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutilainen MH, De Lorenzo F, Stepanova P, et al. . Evidence for an additive neurorestorative effect of simultaneously administered CDNF and GDNF in hemiparkinsonian rats: Implications for different mechanism of action. eNeuro. 2017;4:ENEURO.0117-16.2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5346176</ArticleId><ArticleId IdType="pubmed">28303260</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature. 1992;360:753&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">1281520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendtner M, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature. 1990;345:440&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">2342575</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Korennykh AV, Behrman SL, Walter P. Mammalian endoplasmic reticulum stress sensor IRE1 signals by dynamic clustering. Proc Natl Acad Sci U S A. 2010;107:16113&#x2013;16118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941319</ArticleId><ArticleId IdType="pubmed">20798350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S, Valm AM, Lippincott-Schwartz J. Interacting organelles. Curr Opin Cell Biol. 2018;53:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6241252</ArticleId><ArticleId IdType="pubmed">30006038</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C, Moradi M, Reinhard S, et al. . Dynamic remodeling of ribosomes and endoplasmic reticulum in axon terminals of motoneurons. J Cell Sci. 2021;134:jcs258785.</Citation><ArticleIdList><ArticleId IdType="pubmed">34668554</ArticleId></ArticleIdList></Reference><Reference><Citation>Terasaki M, Reese TS. Interactions among endoplasmic reticulum, microtubules, and retrograde movements of the cell surface. Cell Motil Cytoskeleton. 1994;29:291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">7859292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Whiteus C, Xu CS, et al. . Contacts between the endoplasmic reticulum and other membranes in neurons. Proc Natl Acad Sci U S A. 2017;114:E4859&#x2013;E4867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474793</ArticleId><ArticleId IdType="pubmed">28559323</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, Deitch JS, Blankenhorn EP, et al. . Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci. 2005;236(1-2):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Trieu VN, Uckun FM. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem Biophys Res Commun. 1999;258:685&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">10329446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Wang Y, Chin ER. Activation of the endoplasmic reticulum stress response in skeletal muscle of G93A*SOD1 amyotrophic lateral sclerosis mice. Front Cell Neurosci. 2015;9:170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435075</ArticleId><ArticleId IdType="pubmed">26041991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106:18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y-F, Gendron TF, Zhang Y-J, et al. . Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30:10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP knockin mouse model of ALS. Cell Rep. 2019;26:364&#x2013;373.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, et al. . TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21:552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon CE, Meilandt WJ, Dominguez S, et al. . Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017;9:eaag0394.</Citation><ArticleIdList><ArticleId IdType="pubmed">28814543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh R, Wang L, Wang ES, et al. . Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress. Cell. 2014;158:534&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4244221</ArticleId><ArticleId IdType="pubmed">25018104</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita S, Villalta SA, Feldman HC, et al. . Targeting ABL-IRE1&#x3b1; signaling spares ER-stressed pancreatic &#x3b2; cells to reverse autoimmune diabetes. Cell Metab. 2017;25:883&#x2013;897.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5497784</ArticleId><ArticleId IdType="pubmed">28380378</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno JA, Radford H, Peretti D, et al. . Sustained translational repression by eIF2&#x3b1;-P mediates prion neurodegeneration. Nature. 2012;485:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378208</ArticleId><ArticleId IdType="pubmed">22622579</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira FG, Ping Q, Moreno AJ, et al. . Guanabenz treatment accelerates disease in a mutant SOD1 mouse model of ALS. PLoS ONE. 2015;10:e0135570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545826</ArticleId><ArticleId IdType="pubmed">26288094</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno JA, Halliday M, Molloy C, et al. . Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med. 2013;5:206ra138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24107777</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttunen HJ, Saarma M. CDNF protein therapy in Parkinson's disease. Cell Transplant. 2019;28:349&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628563</ArticleId><ArticleId IdType="pubmed">30947516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C, Chevet E, Oakes SA. Proteostasis control by the unfolded protein response. Nat Cell Biol. 2015;17:829&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546321</ArticleId><ArticleId IdType="pubmed">26123108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl M, Chalazonitis A, Palm E, et al. . Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice. Neurobiol Dis. 2020;134:104696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7000201</ArticleId><ArticleId IdType="pubmed">31783118</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S, Tan J, Miao Y, Sun Z, Zhang Q. Intermittent-hypoxia-induced autophagy activation through the ER-stress-related PERK/eIF2&#x3b1;/ATF4 pathway is a protective response to pancreatic &#x3b2;-cell apoptosis. Cell Physiol Biochem. 2018;51:2955&#x2013;2971.</Citation><ArticleIdList><ArticleId IdType="pubmed">30562747</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S, Tan J, Miao Y, Zhang Q. Crosstalk of ER stress-mediated autophagy and ER-phagy: Involvement of UPR and the core autophagy machinery. J Cell Physiol. 2018;233:3867&#x2013;3874.</Citation><ArticleIdList><ArticleId IdType="pubmed">28777470</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadella R, Voutilainen MH, Saarma M, et al. . Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. J Neuroinflammation. 2014;11:209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275959</ArticleId><ArticleId IdType="pubmed">25511018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovaleva V, Yu L-Y, Ivanova L, et al. . MANF Regulates neuronal survival and UPR through its ER-located receptor IRE1&#x3b1;. Cell Rep. 2023;42:112066.</Citation><ArticleIdList><ArticleId IdType="pubmed">36739529</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007;26:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17300945</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, Barbagallo P, Farrimond L, et al. . Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS/FTD. Stem Cell Reports. 2020;14:892&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal SS, Gomes CM. Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability. Front Cell Neurosci. 2015;9:225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468822</ArticleId><ArticleId IdType="pubmed">26136661</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi V, Petrozziello T, Secondo A. Calcium dyshomeostasis and lysosomal Ca(2+) dysfunction in amyotrophic lateral sclerosis. Cells. 2019;8:1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829585</ArticleId><ArticleId IdType="pubmed">31597311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, Woods I, Villunger A, Strasser A, Prehn JH. Deletion of the BH3-only protein puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in ALS mice. Proc Natl Acad Sci U S A. 2007;104:20606&#x2013;20611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2154478</ArticleId><ArticleId IdType="pubmed">18077368</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Liao Q, Lu K, Zhou J, Huang C, Bi F. Riluzole exhibits no therapeutic efficacy on a transgenic rat model of amyotrophic lateral sclerosis. Curr Neurovasc Res. 2020;17:275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">32271694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Cutting FB, Zhai P, et al. . Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">8967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Wate R, Zhang J, et al. . Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>